Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management

Author(s): Yeh ET, Bickford CL

Abstract

Cancer treatment today employs a combination of chemotherapy, radiotherapy, and surgery to prolong life and provide cure. However, many of these treatments can cause cardiovascular complications such as heart failure, myocardial ischemia/infarction, hypertension, thromboembolism, and arrhythmias. In this article we review the incidence of cardiotoxicity caused by commonly used chemotherapeutic agents as well as discuss the pathogenesis, diagnosis, management, and prevention of these cardiovascular side effects. Cardiotoxicity related to anticancer treatment is important to recognize as it may have a significant impact on the overall prognosis and survival of cancer patients, and it is likely to remain a significant challenge for both cardiologists and oncologists in the future due to an increasing aging population of patients with cancer and the introduction of many new cancer therapies.

Similar Articles

Cardiotoxicity and cardioprotection in childhood cancer

Author(s): Lipshultz SE, Sambatakos P, Maguire M, Karnik R, Ross SW, et al.

Transcription factor GATA4 inhibits doxorubicin-induced autophagy and cardiomyocyte death

Author(s): Kobayashi S, Volden P, Timm D, Mao K, Xu X, et al.

Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The Pediatric Oncology Group experience

Author(s): Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, et al.

Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer

Author(s): Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, et al.

Doxorubicin-induced cardiac toxicity and cardiac rest gated blood pool imaging

Author(s): Aiken MJ, Suhag V, Garcia CA, Acio E, Moreau S, et al.

Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies

Author(s): Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE

Acute chemotherapy-induced cardiomyopathy treated with intracorporeal left ventricular assist device in an 8-year-old child

Author(s): Schweiger M, Dave H, Lemme F, Cavigelli-Brunner A, Romanchenko O, et al.

Successful bridge to recovery with VAD implantation for anthracycline-induced cardiomyopathy

Author(s): Kurihara C, Nishimura T, Nawata K, Kinoshita O, Hisagi M, et al.

Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia

Author(s): Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, et al.

Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure

Author(s): Palazzuoli A, Gallotta M, Quatrini I, Nuti R

Cardiotoxicity in childhood cancer survivors: strategies for prevention and management

Author(s): Harake D, Franco VI, Henkel JM, Miller TL, Lipshultz SE

Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study

Author(s): Thompson PA, Rosner GL, Matthay KK, Moore TB, Bomgaars LR, et al.